Denali Therapeutics price target lowered to $32 from $33 at Wedbush

Wedbush analyst Laura Chico lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $33 and keeps an Outperform rating on the shares. Overall, the Q4 financial results update from the company was largely uneventful, the firm says. Most notable in the update, all key pipeline development timelines remain on track, including the tividenofusp alfa BLA submission, Wedbush adds.